Moderna starts human trials of an mRNA-based flu shot | WHAT REALLY HAPPENED

Moderna starts human trials of an mRNA-based flu shot

Moderna gave its mRNA-based seasonal flu vaccine to the first set of volunteers in a clinical trial, the pharmaceutical company announced today. The start of the trial marks the next stage of the company’s work on this type of vaccine technology after the overwhelming success of its COVID-19 vaccine, which was built using the same strategy.

Before the COVID-19 pandemic, mRNA vaccines were still largely experimental, even as they were heralded as the future of vaccine development. People who get an mRNA vaccine are injected with tiny snippets of genetic material from the target virus. Their cells use that genetic information to build bits of the virus, which the body’s immune system learns to fight against.

The high efficacy of the mRNA COVID-19 vaccines made by Moderna and Pfizer / BioNTech was a major endorsement for this type of vaccine. Now, pharmaceutical companies plan to use this technology to fight other types of infectious diseases, including flu. The flu shots available each year in the United States are usually between 40 and 60 percent effective. The most common shots are made by growing the influenza virus in cells or chicken eggs, and then killing the virus so it’s no longer dangerous. It takes a long time to grow the virus, so companies have to start making the shots around six months ahead of time, based on predictions around which strain of the flu will be circulating that year.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA